Acumen Pharmaceuticals

Q3 FY2026 EarningsQ3 FY26 results beat consensus on both profitability and cash management: GAAP EPS of -$0.35 outperformed the -$0.37 expected, and net loss of $25.4M was narrower than the $29.0M forecast. Operating loss of $25.8M beat the $30.7M consensus due to lower-than-anticipated R&D manufacturing costs. Management confirmed the highly anticipated Phase 2 ALTITUDE-AD topline results for sabirnetug are on track for November 2026, though the cash runway into early 2027 remains a critical focus.